Table 1.
Demographics of HPTN 077 Participants
| Characteristic | Cohort 1 (n=82) | Cohort 2 (n=69) | Total Cohort (n=151) | Data used for modeling (n=133) |
|---|---|---|---|---|
|
| ||||
| Cabotegravir dosing1 | 800 mg IM q 12 wk | 600 mg IM q 8 wk | ||
|
| ||||
| Age (yrs) at Enrollment, median (IQR) | 29.5 (24,41) | 30 (23,36) | 30 (24,39) | 29 (24,38) |
| BMI (kg/m2) at Entry, median (IQR) | 27.4 (24.1,32.6) | 25.7 (22.0,32.0) | 26.8 (23.2,32.3) | 26.6 (23.0,32.8) |
| Weight (kg), median (IQR) | 78.0 (67.6,94.3) | 72.0 (60.2,86.2) | 74.7 (62.15,91.85) | 74.7 (61.0,91.4) |
| Sex at birth2, n (%) | ||||
| Female | 54 (66%) | 46 (67%) | 100 (66%) | 89 (67%) |
| Male | 28 (34%) | 23 (33%) | 51 (34%) | 44 (33%) |
| Race, n (%) | ||||
| Non-Hispanic white | 29 (35%) | 13 (19%) | 42 (28%) | 36 (27%) |
| Non-Hispanic black | 31 (38%) | 33 (48%) | 64 (42%) | 55 (41%) |
| Latino | 19 (23%) | 17 (25%) | 36 (24%) | 35 (26%) |
| Non-Hispanic Asian | 0 (0%) | 3 (4%) | 3 (2%) | 2 (2%) |
| Non-Hispanic mixed/other | 3 (4%) | 3 (4%) | 6 (4%) | 5 (4%) |
1
Cohort 1 received 3 total injections with no load; Cohort 2 received 5 total injections—the first 2 separated by 4 weeks as an initial load, and the last 3 separated by 8 weeks.
2
There were 6 transgender men (TGM) and 1 transgender woman (TGW) in the HPTN 077 study, who were categorized according to sex at birth; that is, TGW with the individuals born male, and TGM with the individuals born female.